tradingkey.logo

AxoGen Inc

AXGN
23.729USD
+0.479+2.06%
Market hours ETQuotes delayed by 15 min
1.09BMarket Cap
LossP/E TTM

AxoGen Inc

23.729
+0.479+2.06%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of AxoGen Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AxoGen Inc's Score

Industry at a Glance

Industry Ranking
2 / 210
Overall Ranking
25 / 4617
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 9 analysts
Buy
Current Rating
28.667
Target Price
+29.01%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

AxoGen Inc Highlights

StrengthsRisks
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.18% year-on-year.
Undervalued
The company’s latest PE is -555.95, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.93M shares, decreasing 1.91% quarter-over-quarter.
Held by Keeley-Teton Advisors, LLC
Star Investor Keeley-Teton Advisors, LLC holds 69.93K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.01.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 8.96, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 60.08M, representing a year-over-year increase of 23.51%, while its net profit experienced a year-over-year increase of 138.11%.

Score

Industry at a Glance

Previous score
8.96
Change
0

Financials

7.10

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.72

AxoGen Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.42, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -555.95, which is -98.81% below the recent high of -6.64 and 0.00% above the recent low of -555.95.

Score

Industry at a Glance

Previous score
7.42
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 2/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.44, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for AxoGen Inc is 28.00, with a high of 34.00 and a low of 26.00.

Score

Industry at a Glance

Previous score
8.44
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts
Buy
Current Rating
28.667
Target Price
+29.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
AxoGen Inc
AXGN
9
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 9.76, which is higher than the Healthcare Equipment & Supplies industry's average of 6.72. Sideways: Currently, the stock price is trading between the resistance level at 26.02 and the support level at 17.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.59
Change
0.17

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MACD(12,26,9)
1.284
Buy
RSI(14)
79.886
Buy
STOCH(KDJ)(9,3,3)
92.628
Overbought
ATR(14)
1.113
High Vlolatility
CCI(14)
137.727
Buy
Williams %R
2.274
Overbought
TRIX(12,20)
0.878
Sell
StochRSI(14)
90.535
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
21.696
Buy
MA10
19.801
Buy
MA20
18.118
Buy
MA50
17.259
Buy
MA100
14.818
Buy
MA200
15.440
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 90.91%, representing a quarter-over-quarter decrease of 0.18%. The largest institutional shareholder is The Vanguard, holding a total of 2.72M shares, representing 5.90% of shares outstanding, with 7.39% increase in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
3

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
First Light Asset Management, LLC
4.53M
+1.23%
BlackRock Institutional Trust Company, N.A.
3.10M
-0.84%
The Vanguard Group, Inc.
Star Investors
2.72M
+7.58%
Morgan Stanley & Co. LLC
1.93M
+21.98%
Balyasny Asset Management LP
1.93M
+183.91%
ArrowMark Colorado Holdings, LLC
1.63M
+2.19%
Soleus Capital Management, L.P.
1.46M
+0.92%
Wasatch Global Investors Inc
Star Investors
1.43M
+85.09%
Assenagon Asset Management S.A.
1.29M
+25.99%
Zaderej (Karen L)
1.14M
+6.62%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 5.63, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
5.63
Change
0
Beta vs S&P 500 index
1.09
VaR
+5.57%
240-Day Maximum Drawdown
+53.80%
240-Day Volatility
+69.03%

Return

Best Daily Return
60 days
+23.06%
120 days
+23.06%
5 years
+36.90%
Worst Daily Return
60 days
-9.04%
120 days
-9.04%
5 years
-23.18%
Sharpe Ratio
60 days
+3.60
120 days
+2.88
5 years
+0.38

Risk Assessment

Maximum Drawdown
240 days
+53.80%
3 years
+67.03%
5 years
+84.64%
Return-to-Drawdown Ratio
240 days
+1.56
3 years
+0.64
5 years
+0.06
Skewness
240 days
+0.45
3 years
+2.06
5 years
+1.47

Volatility

Realised Volatility
240 days
+69.03%
5 years
+66.90%
Standardised True Range
240 days
+3.59%
5 years
+2.80%
Downside Risk-Adjusted Return
120 days
+641.03%
240 days
+641.03%
Maximum Daily Upside Volatility
60 days
+61.78%
Maximum Daily Downside Volatility
60 days
+38.32%

Liquidity

Average Turnover Rate
60 days
+2.82%
120 days
+2.04%
5 years
--
Turnover Deviation
20 days
+201.03%
60 days
+124.18%
120 days
+62.69%

Peer Comparison

Healthcare Equipment & Supplies
AxoGen Inc
AxoGen Inc
AXGN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Hologic Inc
Hologic Inc
HOLX
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI